Incyte Corporation (INCY)
INCY moved a median of +0.05% 30 minutes after news, and +0.19% by the close. How INCY actually reacts to news — the realized, point-in-time move the market made, measured across 633 labeled events over the last three years with zero look-ahead.
INCY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.01% | 51% | 629 |
| 30-min | +0.05% | 53% | 629 |
| 60-min | +0.07% | 53% | 629 |
| to close | +0.19% | 55% | 624 |
| Middle 50% of INCY reactions | -0.58% to +0.65% |
|---|---|
| Median reaction (30-min) | +0.05% |
| Measured reactions | 633 |
Half of all Incyte Corporation news events land between -0.58% and +0.65% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How INCY reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 36 | +0.07% | 64% | +0.23% |
| Analyst downgrades | 33 | -0.64% | 30% | -0.30% |
| Coverage initiations | 27 | +0.24% | 52% | -0.06% |
| Rating reiterations | 185 | -0.03% | 48% | +0.11% |
| Price-target raises | 47 | -0.12% | 40% | -0.24% |
| Price-target cuts | 21 | +0.21% | 62% | +0.33% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how INCY ranks against every other measured name →
That’s how INCY usually reacts — get an email when it moves on news →Email me when INCY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to INCY's baseline. Nothing else.
Recent INCY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Incyte to Report Third Quarter Financial Results | Press release | Business Wire | +0.05% | -0.12% | |
| Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil | Press release | GlobeNewswire | -0.64% | -1.23% | |
| Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva | Press release | Business Wire | +0.38% | +1.22% | |
| Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio | Press release | Business Wire | +0.23% | +1.77% | |
| Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia | Press release | PR Newswire | +0.29% | -0.28% | |
| Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program | Press release | Canada Newswire | +0.10% | -1.45% | |
| Incyte to Present at Upcoming Investor Conferences | Press release | Business Wire | -0.39% | +0.32% | |
| Form 8-K INCYTE CORP For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | -0.39% | +0.32% | |
| Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.78% | — | |
| New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS | Press release | PR Newswire | -0.59% | -1.49% | |
| Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis | Press release | Business Wire | -1.14% | -1.37% | |
| Form 10-Q INCYTE CORP For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.14% | -1.37% | |
| Form 8-K INCYTE CORP For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | +2.67% | +9.19% | |
| Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | Business Wire | +2.67% | +9.19% | |
| Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers | Press release | Business Wire | +0.04% | +0.25% | |
| Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types | Press release | Business Wire | -1.18% | -1.50% | |
| Incyte to Report Second Quarter Financial Results | Press release | Business Wire | -0.90% | -0.68% | |
| Form 8-K INCYTE CORP For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | -0.29% | +0.44% | |
| Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio | Press release | Business Wire | +0.18% | +0.19% | |
| Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis | Press release | Business Wire | +3.43% | +3.46% | |
| Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress | Press release | Business Wire | +3.43% | +3.46% | |
| Form 8-K INCYTE CORP For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +0.84% | +3.66% | |
| Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Press release | Business Wire | +0.84% | +3.66% | |
| Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva | Press release | Business Wire | -2.83% | -4.45% | |
| Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia | Press release | Business Wire | -2.83% | -4.45% | |
| Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival | Press release | Business Wire | -2.83% | -4.45% | |
| Form 8-K INCYTE CORP For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | +0.28% | +1.52% | |
| Form 8-K INCYTE CORP For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | -0.22% | -2.25% | |
| Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders | Press release | Business Wire | -0.22% | -2.25% | |
| Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 | Press release | Business Wire | -0.50% | +1.84% | |
| Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL | Press release | Business Wire | -0.62% | -0.92% | |
| Form DEFA14A INCYTE CORP | SEC filing · Form DEFA14A | SEC EDGAR | +0.07% | -0.01% | |
| Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | Business Wire | -0.22% | -0.26% | |
| Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery | Press release | Business Wire | -0.07% | +0.59% | |
| Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development | Press release | Business Wire | -0.63% | +0.43% | |
| Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress | Press release | Business Wire | +0.00% | -0.87% | |
| Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis | Press release | Business Wire | -1.31% | -1.92% | |
| Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.31% | -1.92% | |
| New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1] | Press release | PR Newswire | +0.89% | +0.62% | |
| Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease | Press release | Business Wire | +0.89% | +0.62% | |
| Incyte to Present at Upcoming Investor Conferences | Press release | Business Wire | +3.12% | +0.86% | |
| Form 10-Q INCYTE CORP For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.12% | +0.86% | |
| Form 8-K INCYTE CORP For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | +1.09% | +3.16% | |
| Form ARS INCYTE CORP For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +3.12% | +0.86% | |
| Form DEF 14A INCYTE CORP For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +3.12% | +0.86% | |
| Form DEFA14A INCYTE CORP | SEC filing · Form DEFA14A | SEC EDGAR | +3.12% | +0.86% | |
| Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer | Press release | Business Wire | +1.09% | +3.16% | |
| Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | Business Wire | +1.09% | +3.16% | |
| MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia | Press release | PR Newswire | +0.44% | -0.93% | |
| Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting | Press release | Business Wire | +0.25% | +0.51% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the INCY section they belong to.
Where else INCY is measured.
INCY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Novan, Inc. (NOVN) | 634 | -0.02% | 45% |
| Zimmer Biomet Holdings, Inc. (ZBH) | 634 | +0.11% | 59% |
| BIOSPECIFICS TECHNOLOGIES (BSTC) | 632 | 0.00% | 43% |
| Danaher Corporation (DHR) | 632 | +0.04% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Incyte Corporation's median reaction calculated?
Every labeled INCY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 633 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of INCY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does INCY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.